TY - JOUR
T1 - Perilesional brain oedema and seizure activity in patients with calcified neurocysticercosis
T2 - a prospective cohort and nested case-control study
AU - Nash, Theodore E.
AU - Pretell, E. Javier
AU - Lescano, Andres G.
AU - Bustos, Javier A.
AU - Gilman, Robert H.
AU - Gonzalez, Armando E.
AU - Garcia, Héctor H.
N1 - Funding Information:
Funding for this study was provided by the US National Institute of Allergy and Infectious Diseases (NIAID), US National Institutes of Health (NIH), and Fogarty International Center (FIRCA grant R03 TW05562). We wish to thank the neurologists of the San Vicente Infectious Disease Service who helped with patient care and management, and the neurologists of other services at the Instituto de Ciencias Neurológicas in Lima, Peru, for referral of patients.
PY - 2008/12
Y1 - 2008/12
N2 - Background: Cysticercosis due to Taenia solium is a cause of adult-acquired seizures and epilepsy even in patients with only calcified larval cysts. Transient perilesional brain oedema is seen around the calcified foci but its importance, association with seizures, incidence, and pathophysiology are unknown. Methods: 110 patients with only calcified lesions and a history of seizures or severe headaches were followed prospectively in a cohort design to assess the incidence of seizure relapse. In a nested case-control substudy, perilesional oedema was assessed by MRI at the time of seizure in symptomatic patients and in matched asymptomatic controls taken from the study population. Findings: Between November, 1999, and December, 2006, 29 patients had an incident seizure during a median follow up of 32·33 (SD 19·99) months, with an estimated 5-year seizure incidence of 36% (95% CI 25% to 49%). 24 of 29 (83%) patients with seizure relapse had an MRI evaluation within 5 days of the event; perilesional oedema was seen in 12 patients (50%) compared with two (9%) of 23 asymptomatic matched controls. Interpretation: Perilesional oedema is common and associated with episodic seizure activity in patients with calcified neurocysticercosis. Our findings are probably representative of symptomatic patients in regions where T solium neurocysticercosis is endemic and suggest a unique and possibly preventable cause of seizures in this population. Funding: US National Institute of Allergy and Infectious Diseases; US National Institutes of Health; Fogarty International Center.
AB - Background: Cysticercosis due to Taenia solium is a cause of adult-acquired seizures and epilepsy even in patients with only calcified larval cysts. Transient perilesional brain oedema is seen around the calcified foci but its importance, association with seizures, incidence, and pathophysiology are unknown. Methods: 110 patients with only calcified lesions and a history of seizures or severe headaches were followed prospectively in a cohort design to assess the incidence of seizure relapse. In a nested case-control substudy, perilesional oedema was assessed by MRI at the time of seizure in symptomatic patients and in matched asymptomatic controls taken from the study population. Findings: Between November, 1999, and December, 2006, 29 patients had an incident seizure during a median follow up of 32·33 (SD 19·99) months, with an estimated 5-year seizure incidence of 36% (95% CI 25% to 49%). 24 of 29 (83%) patients with seizure relapse had an MRI evaluation within 5 days of the event; perilesional oedema was seen in 12 patients (50%) compared with two (9%) of 23 asymptomatic matched controls. Interpretation: Perilesional oedema is common and associated with episodic seizure activity in patients with calcified neurocysticercosis. Our findings are probably representative of symptomatic patients in regions where T solium neurocysticercosis is endemic and suggest a unique and possibly preventable cause of seizures in this population. Funding: US National Institute of Allergy and Infectious Diseases; US National Institutes of Health; Fogarty International Center.
UR - http://www.scopus.com/inward/record.url?scp=55549147120&partnerID=8YFLogxK
U2 - 10.1016/S1474-4422(08)70243-6
DO - 10.1016/S1474-4422(08)70243-6
M3 - Artículo
C2 - 18986841
AN - SCOPUS:55549147120
SN - 1474-4422
VL - 7
SP - 1099
EP - 1105
JO - The Lancet Neurology
JF - The Lancet Neurology
IS - 12
ER -